|
Gene: GADD45G |
Gene summary for GADD45G |
Gene summary. |
Gene information | Species | Human | Gene symbol | GADD45G | Gene ID | 10912 |
Gene name | growth arrest and DNA damage inducible gamma | |
Gene Alias | CR6 | |
Cytomap | 9q22.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | O95257 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10912 | GADD45G | GSM4909286 | Human | Breast | IDC | 5.10e-05 | -2.54e-01 | 0.1081 |
10912 | GADD45G | GSM4909297 | Human | Breast | IDC | 1.43e-10 | 5.56e-01 | 0.1517 |
10912 | GADD45G | GSM4909298 | Human | Breast | IDC | 2.84e-08 | 3.61e-01 | 0.1551 |
10912 | GADD45G | GSM4909301 | Human | Breast | IDC | 4.56e-42 | 1.02e+00 | 0.1577 |
10912 | GADD45G | GSM4909304 | Human | Breast | IDC | 5.48e-06 | 2.52e-01 | 0.1636 |
10912 | GADD45G | GSM4909306 | Human | Breast | IDC | 1.98e-13 | 4.23e-01 | 0.1564 |
10912 | GADD45G | GSM4909308 | Human | Breast | IDC | 1.25e-10 | 4.91e-01 | 0.158 |
10912 | GADD45G | GSM4909311 | Human | Breast | IDC | 1.36e-03 | -8.03e-02 | 0.1534 |
10912 | GADD45G | GSM4909319 | Human | Breast | IDC | 8.29e-08 | -1.45e-02 | 0.1563 |
10912 | GADD45G | GSM4909321 | Human | Breast | IDC | 6.14e-04 | 3.03e-01 | 0.1559 |
10912 | GADD45G | NCCBC3 | Human | Breast | DCIS | 1.17e-02 | -2.17e-01 | 0.1198 |
10912 | GADD45G | P1 | Human | Breast | IDC | 5.22e-04 | -1.80e-01 | 0.1527 |
10912 | GADD45G | DCIS2 | Human | Breast | DCIS | 5.49e-03 | -1.23e-01 | 0.0085 |
10912 | GADD45G | LZE4T | Human | Esophagus | ESCC | 1.17e-17 | 6.71e-01 | 0.0811 |
10912 | GADD45G | LZE7T | Human | Esophagus | ESCC | 3.00e-09 | 7.87e-01 | 0.0667 |
10912 | GADD45G | LZE24T | Human | Esophagus | ESCC | 4.93e-04 | 1.87e-01 | 0.0596 |
10912 | GADD45G | P1T-E | Human | Esophagus | ESCC | 1.19e-03 | 4.05e-01 | 0.0875 |
10912 | GADD45G | P2T-E | Human | Esophagus | ESCC | 9.09e-22 | 6.40e-01 | 0.1177 |
10912 | GADD45G | P4T-E | Human | Esophagus | ESCC | 3.49e-15 | 5.61e-01 | 0.1323 |
10912 | GADD45G | P5T-E | Human | Esophagus | ESCC | 4.68e-04 | 3.66e-01 | 0.1327 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19007441 | Lung | AIS | regulation of p38MAPK cascade | 11/1849 | 47/18723 | 5.19e-03 | 4.46e-02 | 11 |
GO:003109816 | Oral cavity | OSCC | stress-activated protein kinase signaling cascade | 141/7305 | 247/18723 | 5.74e-09 | 1.25e-07 | 141 |
GO:005140316 | Oral cavity | OSCC | stress-activated MAPK cascade | 134/7305 | 239/18723 | 6.02e-08 | 1.09e-06 | 134 |
GO:007030210 | Oral cavity | OSCC | regulation of stress-activated protein kinase signaling cascade | 111/7305 | 195/18723 | 2.82e-07 | 4.34e-06 | 111 |
GO:003287210 | Oral cavity | OSCC | regulation of stress-activated MAPK cascade | 108/7305 | 192/18723 | 8.97e-07 | 1.22e-05 | 108 |
GO:00072548 | Oral cavity | OSCC | JNK cascade | 90/7305 | 167/18723 | 6.49e-05 | 5.26e-04 | 90 |
GO:00463288 | Oral cavity | OSCC | regulation of JNK cascade | 74/7305 | 133/18723 | 7.22e-05 | 5.69e-04 | 74 |
GO:00703045 | Oral cavity | OSCC | positive regulation of stress-activated protein kinase signaling cascade | 66/7305 | 128/18723 | 2.58e-03 | 1.13e-02 | 66 |
GO:00328744 | Oral cavity | OSCC | positive regulation of stress-activated MAPK cascade | 64/7305 | 126/18723 | 4.67e-03 | 1.87e-02 | 64 |
GO:01061065 | Oral cavity | OSCC | cold-induced thermogenesis | 71/7305 | 144/18723 | 7.51e-03 | 2.75e-02 | 71 |
GO:01201615 | Oral cavity | OSCC | regulation of cold-induced thermogenesis | 71/7305 | 144/18723 | 7.51e-03 | 2.75e-02 | 71 |
GO:00016594 | Oral cavity | OSCC | temperature homeostasis | 84/7305 | 174/18723 | 7.84e-03 | 2.87e-02 | 84 |
GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
GO:00463301 | Oral cavity | OSCC | positive regulation of JNK cascade | 46/7305 | 89/18723 | 1.01e-02 | 3.50e-02 | 46 |
GO:19908454 | Oral cavity | OSCC | adaptive thermogenesis | 76/7305 | 157/18723 | 1.02e-02 | 3.52e-02 | 76 |
GO:003109815 | Prostate | Tumor | stress-activated protein kinase signaling cascade | 68/3246 | 247/18723 | 4.03e-05 | 4.62e-04 | 68 |
GO:005140315 | Prostate | Tumor | stress-activated MAPK cascade | 66/3246 | 239/18723 | 4.69e-05 | 5.21e-04 | 66 |
GO:003287215 | Prostate | Tumor | regulation of stress-activated MAPK cascade | 53/3246 | 192/18723 | 2.51e-04 | 2.11e-03 | 53 |
GO:007030215 | Prostate | Tumor | regulation of stress-activated protein kinase signaling cascade | 53/3246 | 195/18723 | 3.80e-04 | 2.95e-03 | 53 |
GO:003806613 | Prostate | Tumor | p38MAPK cascade | 20/3246 | 55/18723 | 5.74e-04 | 4.13e-03 | 20 |
Page: 1 2 3 4 5 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0421824 | Breast | IDC | Cellular senescence | 35/867 | 156/8465 | 5.49e-06 | 7.43e-05 | 5.56e-05 | 35 |
hsa0421022 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
hsa041157 | Breast | IDC | p53 signaling pathway | 16/867 | 74/8465 | 2.86e-03 | 1.86e-02 | 1.39e-02 | 16 |
hsa052147 | Breast | IDC | Glioma | 16/867 | 75/8465 | 3.30e-03 | 2.10e-02 | 1.57e-02 | 16 |
hsa052109 | Breast | IDC | Colorectal cancer | 17/867 | 86/8465 | 5.70e-03 | 3.13e-02 | 2.34e-02 | 17 |
hsa0522010 | Breast | IDC | Chronic myeloid leukemia | 15/867 | 76/8465 | 9.24e-03 | 4.37e-02 | 3.27e-02 | 15 |
hsa052169 | Breast | IDC | Thyroid cancer | 9/867 | 37/8465 | 1.06e-02 | 4.92e-02 | 3.68e-02 | 9 |
hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0421834 | Breast | IDC | Cellular senescence | 35/867 | 156/8465 | 5.49e-06 | 7.43e-05 | 5.56e-05 | 35 |
hsa0421032 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
hsa0411512 | Breast | IDC | p53 signaling pathway | 16/867 | 74/8465 | 2.86e-03 | 1.86e-02 | 1.39e-02 | 16 |
hsa0521413 | Breast | IDC | Glioma | 16/867 | 75/8465 | 3.30e-03 | 2.10e-02 | 1.57e-02 | 16 |
hsa0521014 | Breast | IDC | Colorectal cancer | 17/867 | 86/8465 | 5.70e-03 | 3.13e-02 | 2.34e-02 | 17 |
hsa0522013 | Breast | IDC | Chronic myeloid leukemia | 15/867 | 76/8465 | 9.24e-03 | 4.37e-02 | 3.27e-02 | 15 |
hsa0521614 | Breast | IDC | Thyroid cancer | 9/867 | 37/8465 | 1.06e-02 | 4.92e-02 | 3.68e-02 | 9 |
hsa0516941 | Breast | DCIS | Epstein-Barr virus infection | 46/846 | 202/8465 | 5.60e-08 | 1.13e-06 | 8.33e-07 | 46 |
hsa0421844 | Breast | DCIS | Cellular senescence | 34/846 | 156/8465 | 8.53e-06 | 1.06e-04 | 7.80e-05 | 34 |
hsa0421041 | Breast | DCIS | Apoptosis | 29/846 | 136/8465 | 5.92e-05 | 5.97e-04 | 4.40e-04 | 29 |
hsa0411521 | Breast | DCIS | p53 signaling pathway | 16/846 | 74/8465 | 2.23e-03 | 1.47e-02 | 1.08e-02 | 16 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GADD45G | insertion | In_Frame_Ins | novel | c.323_324insTGCCAC | p.Gly108_Glu109insAlaThr | p.G108_E109insAT | O95257 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
GADD45G | insertion | Frame_Shift_Ins | novel | c.325_326insCACTCCAGCCTGGGCA | p.Glu109AlafsTer46 | p.E109Afs*46 | O95257 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
GADD45G | SNV | Missense_Mutation | novel | c.250T>G | p.Phe84Val | p.F84V | O95257 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
GADD45G | SNV | Missense_Mutation | c.261G>T | p.Glu87Asp | p.E87D | O95257 | protein_coding | tolerated(0.93) | benign(0) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
GADD45G | SNV | Missense_Mutation | novel | c.408N>T | p.Glu136Asp | p.E136D | O95257 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
GADD45G | SNV | Missense_Mutation | novel | c.353A>C | p.His118Pro | p.H118P | O95257 | protein_coding | deleterious(0) | possibly_damaging(0.664) | TCGA-3K-AAZ8-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | sorafenib | PD |
GADD45G | SNV | Missense_Mutation | c.212N>G | p.Asp71Gly | p.D71G | O95257 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-44-7671-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
GADD45G | SNV | Missense_Mutation | novel | c.19C>A | p.Arg7Ser | p.R7S | O95257 | protein_coding | tolerated(0.43) | benign(0.007) | TCGA-58-A46M-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GADD45G | SNV | Missense_Mutation | novel | c.431A>C | p.Glu144Ala | p.E144A | O95257 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-BA-5151-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
GADD45G | SNV | Missense_Mutation | novel | c.395A>G | p.Asp132Gly | p.D132G | O95257 | protein_coding | tolerated(0.05) | possibly_damaging(0.872) | TCGA-VQ-A91K-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10912 | GADD45G | KINASE, TUMOR SUPPRESSOR | ANDROGENS | 15062559 |
Page: 1 |